Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting
Source abstract
Abstract
Many of the therapeutics used for the treatment of brain disorders are not effective and not delivered to the brain due to the complex structure and its barriers. In recent years, many advanced approaches have emerged for the brain drug delivery. Intranasal drug delivery is one of non-invasive approach has gained interest because of direct transport of drugs circumventing the brain barriers through olfactory and trigeminal nerve pathways. Eventhough through these pathways the therapeutics have direct access to the brain, the main limitations of this approach are only limited drug absorption, and nasal permeability. To overcome the issues related to the brain targeting via nasal drug delivery encourage the development of novel drug delivery by combining with nanotechnology. This article will discuss pathways of drug transport form nose to brain, toxicity of nanoparticles role and need of nanostructured lipid carriers (NLCs) and recent advance in combination of NLCs with intranasal drug delivery for targeting the brain.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Lipid Membrane Structure and Behavior · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Ootacamund, India
Funding
Department of Science and Technology · Science and Engineering Research Board
References (45)
Show source-provided references
1. 10.1016/S0928-0987(00)00087-710.1016/S0928-0987(00)00087-7 ↗
2. 10.1602/neurorx.2.4.54110.1602/neurorx.2.4.541 ↗
3. 10.1016/j.tips.2010.03.00310.1016/j.tips.2010.03.003 ↗
4. 10.1016/0006-8993(95)00637-610.1016/0006-8993(95)00637-6 ↗
5. 10.3109/1061186980899787010.3109/10611869808997870 ↗
6. 10.1021/js990029510.1021/js9900295 ↗
7. 10.1002/jps.112210.1002/jps.1122 ↗
8. 10.1016/j.antiviral.2011.09.01210.1016/j.antiviral.2011.09.012 ↗
9. 10.1016/S0168-3659(02)00363-210.1016/S0168-3659(02)00363-2 ↗
10. 10.2174/13816121079116410810.2174/138161210791164108 ↗
11. 10.1038/sj.bjp.070713010.1038/sj.bjp.0707130 ↗
12. 10.1016/S0079-6123(06)62013-X10.1016/S0079-6123(06)62013-X ↗
13. 10.1023/A:101583090763210.1023/A:1015830907632 ↗
14. 10.1007/BF0022107110.1007/BF00221071 ↗
15. 10.1124/jpet.108.14556510.1124/jpet.108.145565 ↗
16. Frey WH · 1995 · 329
17. 10.3109/1071754970905187810.3109/10717549709051878 ↗
18. 10.3233/JAD-1998-110210.3233/JAD-1998-1102 ↗
19. 10.1002/jps.2192410.1002/jps.21924 ↗
20. 10.1016/j.jstrokecerebrovasdis.2004.01.00510.1016/j.jstrokecerebrovasdis.2004.01.005 ↗
21. 10.1016/j.neuroscience.2004.05.02910.1016/j.neuroscience.2004.05.029 ↗
22. Arora P · Drug Deliv Tech · 2002 · 7 · 67
23. 10.1016/j.colsurfb.2015.06.05410.1016/j.colsurfb.2015.06.054 ↗
24. Kimura R · Arch Int Pharmacodyn Ther · 1989 · 302 · 7
25. 10.1002/cne.1014310.1002/cne.10143 ↗
26. 10.1016/j.ejps.2012.12.00710.1016/j.ejps.2012.12.007 ↗
27. 10.1016/j.carbpol.2012.02.05110.1016/j.carbpol.2012.02.051 ↗
28. 10.2147/IJN.S3532910.2147/IJN.S35329 ↗
29. 10.2174/156720104333454210.2174/1567201043334542 ↗
30. 10.1007/s12031-012-9756-y10.1007/s12031-012-9756-y ↗
31. 10.1039/C3AN01621H10.1039/C3AN01621H ↗
32. 10.1016/j.neuro.2012.09.00610.1016/j.neuro.2012.09.006 ↗
33. Han DD · Int J Nanomedicine · 2011 · 6 · 1453
34. 10.1016/j.aquatox.2010.12.00410.1016/j.aquatox.2010.12.004 ↗
35. 10.1016/j.ijpharm.2014.05.00410.1016/j.ijpharm.2014.05.004 ↗
36. 10.1016/j.jpsychires.2012.05.01410.1016/j.jpsychires.2012.05.014 ↗
37. 10.3109/10717544.2013.83871310.3109/10717544.2013.838713 ↗
38. 10.1016/j.addr.2011.11.00210.1016/j.addr.2011.11.002 ↗
39. Eskandari S · Int J Nanomedicine · 2011 · 6 · 363
40. 10.3109/10717544.2013.82294510.3109/10717544.2013.822945 ↗
41. 10.3109/10717544.2014.88599910.3109/10717544.2014.885999 ↗
42. 10.1021/acs.molpharmaceut.6b0058610.1021/acs.molpharmaceut.6b00586 ↗
43. Madane RG · Drug Deliv · 2016 · 23 · 132610.3109/10717544.2014.975382 ↗
44. 10.1039/C5RA19793G10.1039/C5RA19793G ↗
45. 10.3109/21691401.2016.116040710.3109/21691401.2016.1160407 ↗